

SAFETY DATA SHEET

Ce3D[™] Tissue Clearing Solution

Section 1. Identifi	ication
Product identifier	: Ce3D™ Tissue Clearing Solution
Product code	: Not available.
Other means of identification	: Not available.
Product type	: Liquid.
Relevant identified uses of	the substance or mixture and uses advised against
Product use	: Research.
Area of application	: Industrial applications.
Manufacturer	: BioLegend Inc. 8999 BioLegend Way San Diego, CA 92121 – USA Tel: +1-858-455-9588 (7:00AM – 5:00PM PT, M-F)
Supplier's details	 RSM Australia Pty Ltd – On Behalf of BioLegend, Inc. Level 21, 55 Collins Street Melbourne VIC 3000 PO Box 248, Collins Street West VIC 8007 Phone: +61 (0) 3 9286 8040 Fax: +61 (0) 3 9286 8199
e-mail address of person responsible for this SDS	: cs@biolegend.com
Emergency telephone number (with hours of operation)	: +61 (0) 3 9286 8040 (24 hours)
Section 2. Hazard	I(s) identification
Classification of the substance or mixture	: H360 REPRODUCTIVE TOXICITY - Category 1
GHS label elements	

GHS label elements Hazard pictograms



ŝ

Date of issue/Date of revision	: 04/09/2020	Date of previous issue	: No previous validation	Version : 1	1/10		
Supplemental label elements	: Not applie	cable.					
Disposal	national a	spose of contents and containd international regulations		all local, regional,			
Storage	: Not applie	cable.					
Response	: P308 + P313 - IF exposed or concerned: Get medical advice or attention.						
Prevention		btain special instructions be se personal protective equi					
Precautionary statements							
Hazard statements	: H360 - M	ay damage fertility or the u	nborn child.				
Signal word	: DANGER						

Section 2. Hazard(s) identification

Other hazards which do not : None known. result in classification

Section 3. Composition and ingredient information

Substance/mixture	: Mixture
Other means of identification	: Not available.

Ingredient name	% (w/w)	CAS number
N-methylacetamide	≥10 - ≤30	79-16-3

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

Section 4. First aid measures

Description of necessary first aid measures : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower Eye contact eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention. Inhalation Remove victim to fresh air and keep at rest in a position comfortable for breathing. ÷. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours. Skin contact : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse. : Wash out mouth with water. Remove dentures if any. Remove victim to fresh air Ingestion and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Most important symptoms	<u>s/effects, acute</u>	and delayed					
Potential acute health eff	<u>fects</u>						
Eye contact	: No knowr	n significant effects or critic	al hazards.				
Inhalation	: No knowr	n significant effects or critic	al hazards.				
Skin contact	: No knowr	n significant effects or critic	al hazards.				
Ingestion	: No known significant effects or critical hazards.						
Over-exposure signs/syr	<u>nptoms</u>						
Eye contact	: No specif	fic data.					
Date of issue/Date of revision	: 04/09/2020	Date of previous issue	: No previous validation	Version	:1	2/10	

Section 4. First aid measures

: Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations
: Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations
: Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations
dical attention and special treatment needed, if necessary
: In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
: No specific treatment.
: No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

See toxicological information (Section 11)

Section 5. Firefighting measures

Extinguishing media Suitable extinguishing media	: Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	: Do not use water jet.
Specific hazards arising from the chemical	: In a fire or if heated, a pressure increase will occur and the container may burst.
Hazardous thermal decomposition products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides halogenated compounds carbonyl halides
Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

Personal precautions, protect	iv	e equipment and emergency procedures
For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
Environmental precautions	:	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
Methods and material for cont	tai	nment and cleaning up
Small spill	:	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	:	Stop leak if without risk. Move containers from spill area. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.

Section 7. Handling and storage

Precautions for safe handling

recoulding for sale nationing		
Protective measures	:	Put on appropriate personal protective equipment (see Section 8). Avoid exposure - obtain special instructions before use. Avoid exposure during pregnancy. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapour or mist. If during normal use the material presents a respiratory hazard, use only with adequate ventilation or wear appropriate respirator. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	:	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
Conditions for safe storage, including any incompatibilities	:	Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Date of issue/Date of revision	: 04/09/2020	Date of previous issue	: No previous validation	Version : 1	4/10
--------------------------------	--------------	------------------------	--------------------------	-------------	------

Section 8. Exposure controls and personal protection

Control parameters

Occupational exposure limits

None.

Appropriate engineering controls Environmental exposure	 If user operations generate dust, fumes, gas, vapour or mist, use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. Emissions from ventilation or work process equipment should be checked to ensure
controls	they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.
Individual protection measu	<u>ires</u>
Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
Eye/face protection	: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.
Skin protection	
Hand protection	: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.
Body protection	 Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Other skin protection	: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties

Date of issue/Date of revision	: 04/09/2020	Date of previous issue	: No previous validation	Version	:1	5/10	
Flash point	: Not availa	ıble.					
Boiling point	: Not availa	: Not available.					
Melting point	: Not availa	: Not available.					
рН	: Not availa	ible.					
Odour threshold	: Not availa	ıble.					
Odour	: Not availa	ıble.					
Colour	: Clear. Tra	anslucent.					
Physical state	: Liquid.						
<u>Appearance</u>							

Section 9. Physical and chemical properties

Evaporation rate	: Not available.
Flammability (solid, gas)	: Not applicable.
Lower and upper explosive (flammable) limits	: Not available.
Vapour pressure	: Not available.
Vapour density	: Not available.
Relative density	: Not available.
Solubility	: Partially soluble in the following materials: cold water and hot water.
Partition coefficient: n- octanol/water	: Not available.
Auto-ignition temperature	: Not available.
Decomposition temperature	: Not available.
Viscosity	: Not available.
Flow time (ISO 2431)	: Not available.

Section 10. Stability and reactivity

Reactivity	:	No specific test data related to reactivity available for this product or its ingredients.
Chemical stability	:	The product is stable.
Possibility of hazardous reactions	:	Under normal conditions of storage and use, hazardous reactions will not occur. Under normal conditions of storage and use, hazardous polymerisation will not occur.
Conditions to avoid	:	Avoid high temperatures. Keep away from heat and direct sunlight.
Incompatible materials	:	No specific data.
Hazardous decomposition products	:	Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

Information on toxicological effects

Acute toxicity						
Product/ingredient name	Result	S	pecies	Dose	Expo	sure
N-methylacetamide	LD50 Oral	R	at	5 g/kg	-	
Conclusion/Summary	: Not availab	ole.			I	
Irritation/Corrosion						
Conclusion/Summary						
Skin	: Not availab	ole.				
Eyes	: Not availab	ole.				
Respiratory	: Not availab	ole.				
Sensitisation						
Conclusion/Summary						
Skin	: Not availab	ble.				
Respiratory	: Not availab	ble.				
Date of issue/Date of revision	: 04/09/2020	Date of previous issue	: No	previous validation	Version	:1 6/1

Section 11. Toxicological information

Mutagenicity Conclusion/Summary : Not available. Carcinogenicity Conclusion/Summary : Not available. Reproductive toxicity Conclusion/Summary : Not available. Teratogenicity Conclusion/Summary : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Aspiration hazard Not available. Information on likely routes : Routes of entry anticipated: Oral, Dermal, Inhalation. of exposure Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards. Symptoms rolated to the physical, chemical and toxicological characteristics Eye contact : No specific data Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal mafformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal mafformations Skin contact <th></th> <th>5</th>		5
Garcinosenicity Conclusion/Summary : Not available. Reproductive toxicity Conclusion/Summary : Not available. Conclusion/Summary : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Aspiration hazard Not available. Specific target organ toxicity (repeated exposure) Not available. Not available. Potential acute health effects Routes of entry anticipated: Oral, Dermal, Inhalation. of exposure : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Symptoms related to the physical. chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and inmediate effects a swell as chonoic effects from short and long-term exposure		
Conclusion/Summary : Not available. Reproductive toxicity Conclusion/Summary : Not available. Teratogenicity Conclusion/Summary : Not available. Specific target organ toxicity (insple exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Assistation hazard Not available. Not available. Reproductive control in the second exposure) Not available. Potential acute health effects Eye contact : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Symptoms related to the physical. chemical and toxicological characteristics Eye contact : No known significant effects or critical hazards. Symptoms related to the physical. chemical and toxicological characteristics Eye contact : No known significant effects or critical hazards. Symptoms related to the physical. chemical and toxicological characteristics Eye contact : No specific data Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malf		: Not available.
Reproductive toxicity Conclusion/Summary i. Not available. Jeratogenicity Conclusion/Summary ii. Not available. Specific target organ toxicity (repeated exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Aspiration hazard Not available. Potential acute health effects Eye contact ii. No known significant effects or critical hazards. Inhalation ii. No known significant effects or critical hazards. Inhalation ii. No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact ii. No specific data. Inhalation ii. Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact ii. Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact ii. Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Specific atamadificant effects as well as chronic effects from short and long-term exposure short tarm exposure Potential immediate effects ii. Not available.		
Conclusion/Summary : Not available. Teratogenicity Conclusion/Summary : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Aspiration hazard Not available. Information on likely routes : Routes of entry anticipated: Oral, Dermal, Inhalation. of exposure : No known significant effects or critical hazards. Potential acute health effects : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure effects : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immedia		: Not available.
Teratogenicity Conclusion/Summary : Not available; Specific target organ toxicity (single exposure) Not available; Specific target organ toxicity (repeated exposure) Not available; Aspiration hazard Not available; Aspiration hazard Not available; Not available. Specific target organ toxicity (repeated exposure) Not available. Aspiration hazard Not available. Not available; Potential acute health effects Eve contact Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No known significant effects or critical hazards. Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse sympt		
Conclusion/Summary : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Aspiration hazard Not available. Aspiration hazard Not available. Potential acute health offects Eye contact : Routes of entry anticipated: Oral, Dermal, Inhalation. of exposure Potential acute health offects Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No snown significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal mafformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in toetal deaths skeletal mafformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential inmediate : Not available. effects		: Not available.
Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Aspiration hazard Not available. Information on likely routes : Routes of entry anticipated: Oral, Dermal, Inhalation. of exposure Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation Inhalation : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate : Not available. effects : Potential delay		
Not available. Specific target organ toxicity (repeated exposure) Not available. Aspiration hazard Not available. Information on likely routes : Routes of entry anticipated: Oral, Dermal, Inhalation. of exposure Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : Inhalation : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate : Not available. Potential lenged effects : Not available. effe	•	
Not available. Aspiration hazard Not available. Information on likely routes of exposure : Routes of entry anticipated: Oral, Dermal, Inhalation. of exposure Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation Skin contact : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure : Not available. Potential immediate : Not available. effects : Not available.		
Not available. Information on likely routes : Routes of entry anticipated: Oral, Dermal, Inhalation. of exposure Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate Potential immediate : Not available. effects : Not available. effects : Not available.		t <u>y (repeated exposure)</u>
of exposure Potential acute health effects Eye contact No known significant effects or critical hazards. Inhalation No known significant effects or critical hazards. Skin contact No known significant effects or critical hazards. Ingestion No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact No specific data. Inhalation Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate Not available. effects Not available. effec		
Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal matformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal matformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal matformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal matformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate effects Potential immediate : Not available. effects : Not available. Long term exposure : Not available. Potential immediate : Not available. effects : Not available.		: Routes of entry anticipated: Oral, Dermal, Inhalation.
Inhalation : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical. chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate Potential delayed effects : Potential delayed effects : Potential immediate : effects : Potential immediate : Potential immediate : ind available. <td>Potential acute health effects</td> <td>2</td>	Potential acute health effects	2
Skin contact : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential immediate : Not available. effects : Not available.	Eye contact	: No known significant effects or critical hazards.
Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate : Not available. effects : Not available. effects : Not available. effects : Not available. effects : Not available.	Inhalation	: No known significant effects or critical hazards.
Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate Photential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects	Skin contact	: No known significant effects or critical hazards.
Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects : Not available. Long term exposure Potential immediate Potential immediate : Not available. effects : Not available.	Ingestion	: No known significant effects or critical hazards.
Eye contact : No specific data. Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects : Not available. Long term exposure Potential immediate Potential immediate : Not available. effects : Not available. effects : Not available.	Symptome related to the phy	reisel, chemical and toxical aginal characteristics
Inhalation : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate Potential immediate : Not available. Long term exposure Potential immediate : Not available. Long term exposure Potential immediate : Not available. Potential immediate : Not available. effects : Not available.		
reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths increase in foetal weight increase in foetal deaths skeletal malformations : Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate Potential immediate : Not available. effects : Not available. Long term exposure : Not available. Potential immediate : Not available. effects : Not available.		·
Skin contact : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential immediate : Not available. effects : Not available.		reduced foetal weight increase in foetal deaths
reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects Potential immediate : Not available.	Skin contact	: Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths
Short term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Long term exposure : Not available. Potential immediate : Not available. effects : Not available.	Ingestion	reduced foetal weight increase in foetal deaths
Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Long term exposure : Not available. Potential immediate : Not available. effects : Not available.	Delayed and immediate effect	ts as well as chronic effects from short and long-term exposure
effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects : Not available.	Short term exposure	
Long term exposure Potential immediate : Not available. effects		: Not available.
Potential immediate : Not available. effects	Potential delayed effects	: Not available.
effects	Long term exposure	
Potential delayed effects : Not available.		: Not available.

7/10

Section 11. Toxicological information

General	: No known significant effects or critical hazards.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: May damage fertility or the unborn child.

Numerical measures of toxicity

Acute toxicity estimates

Product/ingredient name				(vapours)	Inhalation (dusts and mists) (mg/l)
N-methylacetamide	5000	N/A	N/A	N/A	N/A

Section 12. Ecological information

Toxicity

: Not available. **Conclusion/Summary**

Persistence and degradability

Conclusion/Summary : Not available.

Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
N-methylacetamide	-1.05	-	low

<u>Mobility in soil</u>	
Soil/water partition	: Not available.
coefficient (Koc)	

Other adverse effects : No known significant effects or critical hazards.

Section 13. Disposal considerations

Disposal methods The generation of waste should be avoided or minimised wherever possible. 2 Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and nonrecyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

Date of issue/Date of revision

: 04/09/2020

Section 14. Transport information

	ADG	ADR/RID	IMDG	ΙΑΤΑ
UN number	Not regulated.	Not regulated.	Not regulated.	Not regulated.
UN proper shipping name	-	-	-	-
Transport hazard class(es)	-	-	-	-
Packing group	-	-	-	-
Environmental hazards	No.	No.	No.	No.

Special precautions for user : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Transport in bulk according : Not available. to IMO instruments

Section 15. Regulatory information

Standard for the Uniform Scheduling of Medicines and Poisons

Not regulated.

Model Work Health and Safety Regulations - Scheduled Substances

No listed substance

Australia inventory (AICS) : Not determined.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants Not listed.

Rotterdam Convention on Prior Informed Consent (PIC) Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals Not listed.

Section 16. Any other relevant information

<u>History</u>	
Date of issue/Date of revision	: 04/09/2020
Date of previous issue	: No previous validation
Version	: 1
Prepared by	: Sphera Solutions
Key to abbreviations	: ADG = Australian Dangerous Goods ADR = The European Agreement concerning the International Carriage of Dangerous Goods by Road ATE = Acute Toxicity Estimate BCF = Bioconcentration Factor GHS = Globally Harmonized System of Classification and Labelling of Chemicals IATA = International Air Transport Association IBC = Internediate Bulk Container IMDG = International Maritime Dangerous Goods LogPow = logarithm of the octanol/water partition coefficient MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution) N/A = Not available SUSMP = Standard Uniform Schedule of Medicine and Poisons UN = United Nations

Procedure used to derive the classification

Classification		Justification	
REPRODUCTIVE TOXICITY - Category 1		Calculation method	
References : Work Health and Safety Regulations 2011, as am Preparation of Safety Data Sheets for Hazardous Work Australia Australian Code for the Transport of Dangerous On National Transport Commission		Chemicals, Code of Practice, Safe	

Indicates information that has changed from previously issued version.

Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the abovenamed supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.